Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand the purpose and risks of the study and to provide signed and dated informed consent.~* Men and women aged 18 years or older.~* History of chronic CHF defined as requiring standard HF treatment (including diuretics) for a minimum of 30 days.~* Documented LVEF by any method within 12 months prior to screening.~* The patient has clinical evidence of volume overload at the time of inclusion with at least one of the following:~  * Dyspnea~ * Pulmonary congestion (rales)~ * Peripheral edema~ * Increased jugular venous pressure and/or hepatic congestion with ascites~ * Chest x-ray consistent with CHF~ * Plasma brain natriuretic peptide (BNP) ≥150 pg/mL or N-terminal prohormone brain natriuretic peptide (NT pro-BNP) ≥450 pg/mL~Exclusion Criteria:~* Women who are pregnant (positive pregnancy test), breastfeeding, or who will not adhere to the reproductive precautions as outlined in this protocol and in the informed consent form (ICF).~* Sustained (three blood pressure measurements over 1 hour) systolic blood pressure \<90 mmHg at Screening or Day 0.~* ST segment elevation myocardial infarction or stroke within 30 days prior to Screening.~* Hemodynamically destabilizing cardiac arrhythmia within 30 days prior to Day 0.~* Clinically significant valvular disease.~* Known clinically significant obstructive, restrictive, or hypertrophic cardiomyopathy.~* Cardiac surgery or percutaneous coronary intervention within 30 days prior to Day 0.~* Major surgical procedure within 7 days prior to Day 0.~* Likely to undergo cardiac transplantation, left ventricular assist device (LVAD) or other device implantation, or other cardiac surgery within 3 months after Screening.~* Placement of implantable cardioverter defibrillator or cardiac resynchronization therapy device within 60 days prior to Day 0.~* CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid cardiomyopathy.~* Presence of any clinically significant (as determined by the Investigator) endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, oncologic, and/or other major disease that might interfere with safe and compliant participation in this study.~* Screening laboratory findings as follows:~  * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times the upper limit of normal~ * Total bilirubin \>2.0 mg/dL~ * Serum creatinine \>3.0 mg/dL~ * Hemoglobin \<9.0 g/dL~* Uncontrolled diabetes mellitus as defined by the Investigator (e.g., glycosylated hemoglobin \[HbA1c\] \>9%).~* History of chronic drug/medication abuse within the past 6 months; or current alcohol abuse.~* Co-morbid condition with an expected survival of less than 3 months.~* Known allergy to any vasopressin antagonist or any condition for which treatment with a vasopressin antagonist may present undue risk to the patient.~* Current or recent administration (within 7 days of Day 0) of prohibited medications as listed in Section 8.6.4 .~* Participation in any other investigational study of drugs or devices within 30 days prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lixivaptan (Type: EXPERIMENTAL): Capsule, 100mg Lixivaptan or matching placebo once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).